Pfizer Inc (PFE)

32.16
0.11 0.34
NYSE : Health Care
Prev Close 32.05
Open 32.06
Day Low/High 31.97 / 32.20
52 Wk Low/High 29.83 / 37.39
Volume 17.29M
Avg Volume 22.18M
Exchange NYSE
Shares Outstanding 5.97B
Market Cap 191.27B
EPS 1.20
P/E Ratio 26.93
Div & Yield 1.28 (4.00%)

Latest News

I Can't Swallow the 'Plunge Team'

If it limits volatility, how has the market fallen?

Merck & Co Faces Financial Hit From U.K. Regulator Over Drug Pricing

Merck & Co Faces Financial Hit From U.K. Regulator Over Drug Pricing

Merck & Co may face financial penalties from U.K. regulators after the Competition & Markets Authority released provisional findings of a drug pricing investigation into the American drugmaker.

Merck KGaA Edges Full-Year Guidance Higher After Solid Q1 Earnings

Merck KGaA Edges Full-Year Guidance Higher After Solid Q1 Earnings

Merck KGaA posted slightly stronger-than-expected first quarter earnings Thursday and nudged its full-year profit guidance higher after a key drug approval in the United States.

Pfizer Oncology To Present Data Across 13 Different Types Of Cancer At ASCO 2017 Annual Meeting

Pfizer Inc. (NYSE:PFE) today announced it will present more than 50 abstracts, involving more than 15 clinical-stage assets across solid and hematologic tumors and 12 mechanisms of action, at the 53 rd Annual Meeting of the...

Pfizer Invites Public To View And Listen To Webcast Of June 9 Conference Call With Analysts To Review Oncology Business And ASCO Data Presentations

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Friday, June 9, 2017 at 11:00 a.

Jim Cramer Talks Home Depot, TJX Companies, Ford, Apple, Pfizer, Nike, Target and Alibaba

Jim Cramer Talks Home Depot, TJX Companies, Ford, Apple, Pfizer, Nike, Target and Alibaba

TheStreet's Jim Cramer weighs in on Home Depot, TJX Companies, Ford, Apple, Pfizer, Nike, Target and Alibaba.

Jim Cramer on Citigroup's Downgrade of Pfizer

Jim Cramer on Citigroup's Downgrade of Pfizer

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said earnings matter more than a Citigroup note saying that Pfizer may buy Allergan.

Jim Cramer: Warren Buffett Views Apple as a Consumer Products Company

Jim Cramer: Warren Buffett Views Apple as a Consumer Products Company

TheStreet's Jim Cramer said Berkshire Hathaway CEO Warren Buffett views Apple as a consumer products company,

Jim Cramer -- Citi's Downgrade of Pfizer Not Totally Reasonable

Jim Cramer -- Citi's Downgrade of Pfizer Not Totally Reasonable

Citigroup had a 'thoughtful' research piece on Pfizer, but downgrading it partly based on 'transaction risk' seems unreasonable, Cramer said.

Here Are Some of Congress' Favorite Stocks

Here Are Some of Congress' Favorite Stocks

While hard at work in Washington, a handful of members of Congress have also been busy trading stocks.

Cancer Immunotherapy Fallout From Roche's Bladder Cancer Failure

Cancer Immunotherapy Fallout From Roche's Bladder Cancer Failure

Will the FDA revoke Roche's accelerated approval for Tecentriq in bladder cancer?

Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy

Collaboration combines Pfizer's heritage in Rare Disease, capabilities in gene therapy, and expertise in hemophilia with Sangamo's deep knowledge in genomic therapies

Allergan Starts 'Pivotal' 2017 With a Beat, Plus Jim Cramer's Take

Allergan Starts 'Pivotal' 2017 With a Beat, Plus Jim Cramer's Take

Allergan shares had risen $2.55, or 1.05%, in premarket trading to $244.50.

Roche's Loss In Bladder Cancer Lifts Astrazeneca and Could Boost Bristol-Myers

Roche's Loss In Bladder Cancer Lifts Astrazeneca and Could Boost Bristol-Myers

Roche, the Swiss drugmaker, was let down by Tecentriq in clinical trials providing scope for Astra to close the gap and a possible boost for Bristol on Wednesday

Reaffirming Our Rating on Allergan After Earnings

The company has overcome some of the recent bearish expectations.

M&A Talks May Take Center Stage in Allergan's 1Q Earnings Call

M&A Talks May Take Center Stage in Allergan's 1Q Earnings Call

Pfizer CEO Ian Read last week was forced to field questions about M&A and there's a good chance Allergan won't be any different.

Allergan Must Show Mergers, Drug Pipeline Can Make Up For Lost Sales

Allergan Must Show Mergers, Drug Pipeline Can Make Up For Lost Sales

Analysts estimate total revenue will fall 6.9% to $3.53 billion in the quarter due to the loss of patent exclusivity on some drugs and divestitures of major business lines.

Weekly Roundup: Old Trends Kick Into Gear

Selling premium on big names vs. buying premium has been the superior strategy this earnings season.

(Photo: PATH/Will Boase)

Pfizer Inc., the Bill & Melinda Gates Foundation, and the Children's Investment Fund Foundation (CIFF) today announced a multi-year extension of their collaboration to further broaden access to Pfizer's all-in-one...

Deals of the Week: Waiting for Clarity

Deals of the Week: Waiting for Clarity

The week's action suggests other dealmakers may be thinking the same thing as Pfizer CEO Ian Read.

Phase 3 OCTAVE Studies Of Oral Tofacitinib In Ulcerative Colitis Results Published In The New England Journal Of Medicine

Pfizer Inc. (NYSE:PFE) announced today that detailed results from the Phase 3 Oral Clinical Trials for tof Acitinib in ulcerati VE colitis (OCTAVE) clinical program were published in The New England Journal of Medicine...

Pfizer Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For XELJANZ® (tofacitinib Citrate) For The Treatment Of Adult Patients With Active Psoriatic Arthritis

Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for XELJANZ ® (tofacitinib citrate) 5 mg twice daily (BID) for...

Apple Anticipation Leads to Wall Street Jitters, Now Markets Wait for Fed

Apple Anticipation Leads to Wall Street Jitters, Now Markets Wait for Fed

Two question markets hover over Wall Street on Tuesday, leading to jittery trading through the day's session.

Stocks Mixed as Wall Street Awaits Apple's Earnings

Stocks Mixed as Wall Street Awaits Apple's Earnings

Stocks are narrowly mixed Tuesday afternoon in the wait for earnings from world's largest company Apple.

Closing Out Pfizer Position

Plus, an update on Merck.